Sph-biocad (hk) Limited
Clinical trials sponsored by Sph-biocad (hk) Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody BCD-261 put to the test in healthy volunteers Results expected Oct 2026 (estimated)
-
New shot shows promise for tough psoriasis cases
Disease control CompletedThis Phase 3 trial tested netakimab, a biologic drug given as a shot, against a placebo in 202 Chinese adults with moderate-to-severe plaque psoriasis. The main goal was to see if netakimab could improve skin symptoms by at least 75% (PASI75) or achieve clear/almost clear skin (s…
Phase 3 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug shows promise for spine arthritis in chinese patients
Disease control CompletedThis study tested a new drug, netakimab, in 113 Chinese adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The goal was to see if netakimab works better than a placebo (a dummy treatment) at reducing symptoms. Participants received…
Phase 3 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC